Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: type 1 diabetes

When Is Arthroplasty Recommended? New ACR/AAHKS Guideline Offers Considerations for Timing of Elective Hip or Knee Arthroplasty

Ruth Jessen Hickman, MD  |  November 1, 2023

The ACR released a new arthroplasty guideline in an effort to remedy significant & detrimental delays faced by osteoarthritis or osteonecrosis patients who require surgical intervention.

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone Disorders Tagged with:arthroplastyrecommendations

Case Report: Hajdu-Cheney Syndrome

Ibtissam Gad, MD, Firas Askar, MD, Sudhaker Rao, MD, & Ayad Alhatib, MD  |  October 11, 2023

Hajdu-Cheney syndrome (HCS) is a rare connective tissue disease, with fewer than 100 cases reported worldwide.1 Hallmark features include acro-osteolysis (i.e., resorption of the distal phalanges of the hands and feet), osteoporosis, facial dysmorphisms, and craniofacial and dental abnormalities. Patients often have short stature and can have neuroanatomical deformities causing intellectual disabilities. These patients can…

Filed under:ConditionsOsteoarthritis and Bone DisordersOther Rheumatic Conditions Tagged with:acro-osteolysiscase reportHajdu-Cheney syndrome

Case Report: Giant Cell Arteritis-Related Stroke

Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO  |  September 10, 2023

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

Filed under:ConditionsHome SliderVasculitis Tagged with:case reportGCAgiant cell arteritis (GCA)stroke

FDA Commissioner Charts Potential & Challenges of Emerging Technologies in Patient Care

Ryan Basen  |  June 20, 2023

Disparities, representativeness, algorithmic bias, the disruptive emergence of large language models and continued misinformation spread are key issues poised to transform patient care in American healthcare, FDA Commissioner Robert M. Califf, MD, said during a recent event.

Filed under:Meeting Reports Tagged with:patient engagementRobert M. CaliffTechnologyU.S. Food and Drug Administration (FDA)

How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients

Emily Molina, MD  |  June 9, 2023

My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…

Filed under:ConditionsHome SliderPatient Perspective Tagged with:Dietdietary supplementpatient communication

Point-of-Care Uric Acid Testing

Samantha C. Shapiro, MD  |  March 1, 2023

In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for…

Filed under:ConditionsEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:EULARGoutpoint-of-careTestingUric acid

A World of Difference: Updates from the Global Rheumatology Summit

Jason Liebowitz, MD, FACR  |  January 20, 2023

The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.

Filed under:ACR ConvergenceConditionsMeeting ReportsMyositis Tagged with:ACR Convergence 2022Global Rheumatology Summitidiopathic inflammatory myositisMentorshippatient accessWorkforce

Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?

Samantha C. Shapiro, MD  |  December 6, 2022

How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022belimumabcyclophosphamideLupus nephritismycophenolate mofetilprednisonepregnancyreproductive carerituximabsystemic lupus erythematosus (SLE)tocilizumabvoclosporin

To Treat or Not to Treat? The Great Debate on Treatment of Subclinical Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  December 6, 2022

PHILADELPHIA—One of the great advancements in the field of rheumatology in recent years has been the increased understanding of various stages of disease in rheumatoid arthritis (RA), including what is termed subclinical rheumatoid arthritis. However, questions remain regarding whether to treat patients with subclinical disease and whether treatment of these patients has implications in preventing…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2022pre-rheumatoid arthritisRheumatoid arthritis

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsAPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences